Ophthalmology Amniotic Membrane Market Trends, Size, Growth & Forecast 2028
The Global Ophthalmology Amniotic Membrane Market is expected to grow at a high CAGR of 12.5% during the forecasting period (2021-2028).
(EMAILWIRE.COM, September 17, 2021 )
Market Overview
The amniotic membrane is the placenta's innermost layer, which contains tissue and cells, which act as a wound healing for the re-boom of gentle tissue. These amniotic membranes are utilized in eye surgery for recuperation and changing the broken eye tissues because the biologically active cells are present within the epithelial and stromal layer of the Amniotic membrane release the growth elements and cytokines with anti-inflammatory, anti-immunogenic, and anti-fibrotic houses.
View full report: https://bit.ly/3Cj5wEl
Market Dynamics:
The market growth is driven by the rising demand for the use of amniotic membrane as a biological bandage suitable to be used on the attention surface because of its houses together with skinny, lightweight, elastic, and obvious. These membranes are used to deal with chemical burns, cornea ulcers, and disorders main to ulcerations for the duration of the surgical methods related to the attention tissue excision.
The market is ruled by the presence of several ophthalmology amniotic membrane products. For example, Dehydrated AmnioMatrix evolved by Next Biosciences is a dry amniotic membrane with the epithelial layer of cells eliminated. It acts as a scaffold to which new cells can grow as soon as positioned on the wound. There is an increase in the research and improvement sports for developing ophthalmology amniotic membranes over the forecasted length.
The market is witnessing the submitting of the latest patents related to the ophthalmology amniotic membrane. For instance, in May 2018, TissueTech Inc have been offered patent 9,808,491 through the U.S. Patent Trademark Office. The patent covers using a gel composition comprising a morselized placental amniotic membrane and/or morselized umbilical twine as a method for treating an ocular wound or repairing damaged ocular tissue.
The growth in the wide variety of accreditation from the distinct organizations and associations to several marketplace players shall undoubtedly impact the market. For instance, in January 2020, LifeCell International had obtained accreditation from the American Association of Tissue Banks (AATB) for its beginning tissue merchandise, including the placenta, umbilical twine, amniotic fluid, and placental amniotic membrane. This accreditation would position LifeCell as the first & best enterprise in India and out of doors the USA to receive this accreditation. This accreditation certifies the complete manner of consent, beginning tissue acquisition, processing, launch, storage, and distribution.
Segment Analysis
By Product Type
• Cryopreserved Amniotic Membrane
• Lyophilization Amniotic Membrane
By End-User
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Research and Academic Institutes
Geographical Presentation
By region, the global ophthalmology amniotic membrane market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the global ophthalmology amniotic membrane market due to many companies developing the ophthalmology amniotic membrane. The presence of well-developed healthcare infrastructure with increased healthcare spending shall positively impact the market. According to the Committee for a Responsible Federal Budget, healthcare spending is highest in the United States than in other countries. Healthcare spending was USD 3.5 trillion in the United States in 2017.
The Asia-Pacific region is expected to have a significant market share due to increased investment in the research and development activities for ophthalmology amniotic membranes. Several multinational companies are investing in developing countries, especially India, China, and Japan. The market is witnessing technological advancement for developing ophthalmology amniotic membranes. Growing awareness, rising disposable income, and growing purchasing power shall stimulate market growth over the forecasted period.
Download free sample: https://bit.ly/3EpOPJp
Competitive Analysis
The global ophthalmology amniotic membrane market is highly competitive with the presence of several domestic and international players. FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, and MiMedx Group, Inc are leading market players with a significant market share. Companies are following new product launches, product diversification, market expansion strategies for increasing their market penetration.
The market entry of new players intensifies the market competition. For instance, in July 2018, BioStem Life Sciences had entered the market with four placental-derived tissue products, including the multiple indications, including ophthalmology, orthopedic and advanced wound care markets. These four products are an amniotic tissue allograft flowable matrix, a chorion-free amniotic tissue allograft membrane, an amniotic tissue allograft membrane with a chorion layer, and an extracellular amniotic membrane allograft for ocular repair.
The companies enter into collaborations, mergers, strategic partnerships, purchasing agreements, and acquisitions to increase the demand for ophthalmology amniotic membrane and their expansion across the globe. For instance, in December 2017, AMNIOX Medical, Inc. (a TissueTech, Inc. company) had awarded a group purchasing agreement for Regenerative Skin Grafting Products with Premier. This agreement would allow the premier members to take advantage of special terms pre-negotiated by Premier for the full AMNIOX Medical portfolio of the wound and surgical solutions, known under the respective NEOX CLARINEX brand names.
In March 2017, Altacor had entered into the collaboration with NuVision Biotherapies to distribute the sight-saving therapy, Omnigen in England, Scotland, and Wales. In October 2017, Bio-Tissue had entered into a strategic agreement with Bright Optical for bringing the PROKERA to the Canadian eyecare professionals market. In July 2016, Derma Sciences, Inc. had acquired BioD, LLC for an immediate transaction value of $21.3 million and a potential total transaction value of an estimated $77.8 million. BioD would operate as a wholly-owned subsidiary of Derma Sciences.
The market players are also investing to increase their production capabilities and market expansion around the globe. For instance, in June 2019, TissueTech, Inc., had closed an $82.25m in Series C equity financing. This funding would be used for regulatory approvals from the FDA for several of its development projects to comply with the agency’s new guidance documents and support ongoing commercial development.
Related Topic's
Ophthalmic devises Market, Ophthalmic Diagnostic Equipment Market, Ophthalmic Lasers Market, Ophthalmic Loupes Market, Ophthalmic Knives Market
Market Overview
The amniotic membrane is the placenta's innermost layer, which contains tissue and cells, which act as a wound healing for the re-boom of gentle tissue. These amniotic membranes are utilized in eye surgery for recuperation and changing the broken eye tissues because the biologically active cells are present within the epithelial and stromal layer of the Amniotic membrane release the growth elements and cytokines with anti-inflammatory, anti-immunogenic, and anti-fibrotic houses.
View full report: https://bit.ly/3Cj5wEl
Market Dynamics:
The market growth is driven by the rising demand for the use of amniotic membrane as a biological bandage suitable to be used on the attention surface because of its houses together with skinny, lightweight, elastic, and obvious. These membranes are used to deal with chemical burns, cornea ulcers, and disorders main to ulcerations for the duration of the surgical methods related to the attention tissue excision.
The market is ruled by the presence of several ophthalmology amniotic membrane products. For example, Dehydrated AmnioMatrix evolved by Next Biosciences is a dry amniotic membrane with the epithelial layer of cells eliminated. It acts as a scaffold to which new cells can grow as soon as positioned on the wound. There is an increase in the research and improvement sports for developing ophthalmology amniotic membranes over the forecasted length.
The market is witnessing the submitting of the latest patents related to the ophthalmology amniotic membrane. For instance, in May 2018, TissueTech Inc have been offered patent 9,808,491 through the U.S. Patent Trademark Office. The patent covers using a gel composition comprising a morselized placental amniotic membrane and/or morselized umbilical twine as a method for treating an ocular wound or repairing damaged ocular tissue.
The growth in the wide variety of accreditation from the distinct organizations and associations to several marketplace players shall undoubtedly impact the market. For instance, in January 2020, LifeCell International had obtained accreditation from the American Association of Tissue Banks (AATB) for its beginning tissue merchandise, including the placenta, umbilical twine, amniotic fluid, and placental amniotic membrane. This accreditation would position LifeCell as the first & best enterprise in India and out of doors the USA to receive this accreditation. This accreditation certifies the complete manner of consent, beginning tissue acquisition, processing, launch, storage, and distribution.
Segment Analysis
By Product Type
• Cryopreserved Amniotic Membrane
• Lyophilization Amniotic Membrane
By End-User
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Research and Academic Institutes
Geographical Presentation
By region, the global ophthalmology amniotic membrane market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the global ophthalmology amniotic membrane market due to many companies developing the ophthalmology amniotic membrane. The presence of well-developed healthcare infrastructure with increased healthcare spending shall positively impact the market. According to the Committee for a Responsible Federal Budget, healthcare spending is highest in the United States than in other countries. Healthcare spending was USD 3.5 trillion in the United States in 2017.
The Asia-Pacific region is expected to have a significant market share due to increased investment in the research and development activities for ophthalmology amniotic membranes. Several multinational companies are investing in developing countries, especially India, China, and Japan. The market is witnessing technological advancement for developing ophthalmology amniotic membranes. Growing awareness, rising disposable income, and growing purchasing power shall stimulate market growth over the forecasted period.
Download free sample: https://bit.ly/3EpOPJp
Competitive Analysis
The global ophthalmology amniotic membrane market is highly competitive with the presence of several domestic and international players. FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, and MiMedx Group, Inc are leading market players with a significant market share. Companies are following new product launches, product diversification, market expansion strategies for increasing their market penetration.
The market entry of new players intensifies the market competition. For instance, in July 2018, BioStem Life Sciences had entered the market with four placental-derived tissue products, including the multiple indications, including ophthalmology, orthopedic and advanced wound care markets. These four products are an amniotic tissue allograft flowable matrix, a chorion-free amniotic tissue allograft membrane, an amniotic tissue allograft membrane with a chorion layer, and an extracellular amniotic membrane allograft for ocular repair.
The companies enter into collaborations, mergers, strategic partnerships, purchasing agreements, and acquisitions to increase the demand for ophthalmology amniotic membrane and their expansion across the globe. For instance, in December 2017, AMNIOX Medical, Inc. (a TissueTech, Inc. company) had awarded a group purchasing agreement for Regenerative Skin Grafting Products with Premier. This agreement would allow the premier members to take advantage of special terms pre-negotiated by Premier for the full AMNIOX Medical portfolio of the wound and surgical solutions, known under the respective NEOX CLARINEX brand names.
In March 2017, Altacor had entered into the collaboration with NuVision Biotherapies to distribute the sight-saving therapy, Omnigen in England, Scotland, and Wales. In October 2017, Bio-Tissue had entered into a strategic agreement with Bright Optical for bringing the PROKERA to the Canadian eyecare professionals market. In July 2016, Derma Sciences, Inc. had acquired BioD, LLC for an immediate transaction value of $21.3 million and a potential total transaction value of an estimated $77.8 million. BioD would operate as a wholly-owned subsidiary of Derma Sciences.
The market players are also investing to increase their production capabilities and market expansion around the globe. For instance, in June 2019, TissueTech, Inc., had closed an $82.25m in Series C equity financing. This funding would be used for regulatory approvals from the FDA for several of its development projects to comply with the agency’s new guidance documents and support ongoing commercial development.
Related Topic's
Ophthalmic devises Market, Ophthalmic Diagnostic Equipment Market, Ophthalmic Lasers Market, Ophthalmic Loupes Market, Ophthalmic Knives Market
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results